TEM

Tempus AI

Stock
Stock
ISIN: US88023B1035
Ticker: TEM
US88023B1035
TEM

Price

Price

Frequently asked questions

What is Tempus AI's market capitalization?

The market capitalization of Tempus AI is $8.26B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Tempus AI?

Tempus AI's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$8.287. EPS indicates the company's profitability on a per-share basis.

What is Tempus AI's revenue over the trailing twelve months?

Over the trailing twelve months, Tempus AI reported a revenue of $640.44M.

What is the EBITDA for Tempus AI?

Tempus AI's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$656.16M. EBITDA measures the company's overall financial performance.

How many employees does Tempus AI have, and what sector and industry does it belong to?

Tempus AI employs approximately 2,300 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Tempus AI's shares?

The free float of Tempus AI is 57.12M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$8.26B

EPS (TTM)

 
-$8.287

Free Float

 
57.12M

Revenue (TTM)

 
$640.44M

EBITDA (TTM)

 
-$656.16M

Pricing

52W span
$22.89$79.49

Information

Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.

2,300

Biotechnology & Drugs

Health Care

Identifier

ISIN

US88023B1035

Primary Ticker

TEM
Join the conversation